We are live on ! Find out more
NBRV

Nabriva Therapeutics plc Ordinary Shares Ireland

Delisted

NBRV was delisted on the 31st of July, 2023.

50 hedge funds and large institutions have $37.3M invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2019 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

75% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 8

26% more call options, than puts

Call options by funds: $103K | Put options by funds: $82K

22% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 9

14% more funds holding

Funds holding: 4450 (+6)

20% less capital invested

Capital invested by funds: $46.6M → $37.3M (-$9.3M)

Holders
50
Holders Change
+6
Holders Change %
+13.64%
% of All Funds
0.99%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
14
Increased
11
Reduced
9
Closed
8
Calls
$103K
Puts
$82K
Net Calls
+$21K
Net Calls Change
-$172K

NBRV Hedge Fund Activity: Q4 2019 in Review

50 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q4 2019, worth a combined $37.3M — down 20% from $46.6M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new NBRV positions and 8 closed out — a net gain of 6 holders — while 11 added to existing stakes and 9 trimmed.

The largest buyer was CVI Holdings, opening a new position worth an estimated $6.36M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $886K sold.

  • 50 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q4 2019, up from 44 in Q3 2019.
  • Funds reported $37.3M of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q4 2019, down 20% quarter-over-quarter.
  • 14 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q4 2019 and 8 closed out, a net change of +6 holders.
  • The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q4 2019 was CVI Holdings, an estimated $6.36M added.
  • The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q4 2019 was JP Morgan Chase, an estimated $886K sold.

Based on aggregated 13F filings for Q4 2019.